Yes - just to clarify though, Revascor is an MPC product. Rem-L or the brand Ryoncil is MSC. Hopefully both will become marketable brands, as I believe they will really benefit patients.
On the commercial front, partnerships become much more conceivable if potential partners, too, can see the value, a lot of which is now becoming discernible, if not obvious, so long as you do the work to understand what it is all about. @nippy may be right.
MSB CC Transcript 29 Aug 24, page-41
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.055(3.77%) |
Mkt cap ! $1.729B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.54 | $1.45 | $6.072M | 4.049M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5951 | $1.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 133644 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |